CAJ | 학술논문

2012年的第54届美国血液学会(ASH)年会对于淋巴瘤而言或许具有“革命性”的意义,会议上首次明确提出“远离化疗”治愈淋巴瘤的梦想.而这一观点的提出并非凭空想象.随着对淋巴瘤本质的认识愈加深入,针对淋巴肿瘤细胞表面抗原、细胞内信号转导通路和细胞微环境的靶向药物的研发已取得明显进展.特别是针对惰性B细胞淋巴瘤的靶向药物组合在临床研究中已显示出超越传统化疗方案联合靶向药物的疗效,而且安全性更好.靶向治疗在侵袭性B细胞淋巴瘤和外周T/NK细胞淋巴瘤方面也显示了良好的前景,相信不久的将来定能有所突破.
2012년적제54계미국혈액학회(ASH)년회대우림파류이언혹허구유“혁명성”적의의,회의상수차명학제출“원리화료”치유림파류적몽상.이저일관점적제출병비빙공상상.수착대림파류본질적인식유가심입,침대림파종류세포표면항원、세포내신호전도통로화세포미배경적파향약물적연발이취득명현진전.특별시침대타성B세포림파류적파향약물조합재림상연구중이현시출초월전통화료방안연합파향약물적료효,이차안전성경호.파향치료재침습성B세포림파류화외주T/NK세포림파류방면야현시료량호적전경,상신불구적장래정능유소돌파.
The 54th ASH annual meeting should be considered as a revolution for treatment of lymphoma."Keep away from chemotherapy" will not be just a dream,it based on the deep understand of lymphoma genesis and quick development of different targeted agents.The typical examples are the dramatic novel agents targeting B cell receptor signaling pathway and microenvironment.There combination,such as R-square regimen,showed unbelievable efficacy in indolent B cell lymphomas and tiny side effects.It is sure that therapy breakthroughs in aggressive B cell lymphomas and T/NK cell lymphomas are in the very near future.